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MES counts depending on the type of prosthetic valve
inserted have been reported.1-4
The purpose of this study was the comparison of MES
prevalence and counts between patients having St Jude
Medical valves (SJM; St Jude Medical, Inc, St Paul,
Minn) and patients having the ATS valve (ATS Medical,
Inc, Minneapolis, Minn).
Patients and methods
Patients. The medical records of all patients operated on
between January 1995 and December 1997 were reviewed.
Four cardiac surgeons, using a standardized technique, had
performed all operations. Valves were inserted in the supra-
annular position. ATS standard, ATS standard “soft-cuff,”
ATS-AP, SJM standard, SJM-HP, or SJM Masters prostheses
were implanted in all patients. No anatomic or clinical crite-
ria were applied for the choice of valve. Valves were chosen
at the discretion of the cardiac surgeon, on the basis of per-
sonal preference.
All patients had undergone examination of the extracranial
arteries supplying the brain with continuous wave Doppler
The potential of transcranial Doppler sonography in thedetection of microembolic signals (MES) has been
described in several stroke-prone patient groups, includ-
ing patients with prosthetic cardiac valves. The prognos-
tic relevance of MES concerning prediction of clinically
manifest brain embolism was shown to be marginal1,2 or
even lacking.3-5 Still, a relation between MES counts and
prevalence of neuropsychologic deficit in persons with
artificial heart valves was recently described.6 This issue
is of particular interest, because significant differences in
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and—in selected cases—duplex ultrasound as part of the rou-
tine preoperative assessment. Presence of hemodynamically
significant carotid disease (>70% luminal stenosis on contin-
uous wave Doppler ultrasound), as well as perioperative
stroke, served as exclusion criteria. A total of 239 patients
were identified and received a written invitation to participate
in this study. Of these invitees, 191 patients attended, 12
(6.3%) of whom were excluded because of insufficient tem-
poral bone window. Thus, 179 patients, 98 men and 81
women, aged 61 ± 11 years (mean ± SD), were enrolled in
this study after giving informed consent. One hundred ten
patients had undergone surgery for aortic valve replacement
(AVR), 39 for mitral valve replacement (MVR), and the
remaining 30 for both aortic and mitral valve replacement
(DVR). The interval between transcranial Doppler monitor-
ing and valve insertion was 15 months (13-17 months; medi-
an and 95% confidence intervals). All patients were receiving
warfarin at the time of the transcranial Doppler study (target
international normalized ratio 3-3.5). The actual international
normalized ratio at the time of monitoring was not evaluated.
Methods. A detailed neurologic examination was per-
formed in all cases. Subsequently, the middle cerebral arteries
were identified at a depth of 52 to 58 mm and continuously
insonated for 60 minutes with the 2-MHz transducers of a
pulsed ultrasound machine (Multi-Dop X-4; DWL Elek-
tronische Systeme GmbH, Sipplingen, Germany). Settings of
the Doppler machine were as follows: power 110 mW, sample
volume 5 to 8 mm, low-pass filter 80 kHz, high-pass filter 100
Hz, and sweep 5 seconds. These settings were used through-
out the study. Bilateral monitoring was not feasible in 17
patients because of insufficient temporal bone window on one
side. All monitoring sessions were evaluated online and
recorded on digital audiotapes using an 8-channel digital
audiotape recorder (TASCAM DA 88; TASCAM America,
Montebello, Calif) for later re-evaluation. This was performed
by assigning 15 random tapes (30 hours of monitoring data) to
a second examiner, blinded both to the clinical details of the
involved patients and to the results of the first observer. Both
observers were asked to note the exact position of each detect-
ed MES, based on the display of the digital audiotape recorder.
MES were identified according to criteria established in a
recent consensus.7 Their count was expressed as mean
between the right and left middle cerebral arteries in bilateral-
ly monitored patients. Otherwise, the MES count detected in
the monitored middle cerebral artery was used.
Statistical analysis. Normally distributed data were
expressed as mean ± standard deviation (SD) and compared
by means of the 2-sample t test. Non-normally distributed
data were expressed as median and 95% confidence intervals
and compared by means of the Mann-Whitney U test. The
hypothesis that MES counts significantly differed depending
on valve position was tested with the Kruskal-Wallis test for
each valve type. The χ2 test was used for comparison of fre-
quency distributions; when the sample size was low, the
Fisher exact test was used instead. The Spearman rank corre-
lation was used to examine the influence of valve duration
and valve size on MES counts.
A binary logistic regression model (using Minitab version
13) was applied to evaluate the influence of valve type, valve
position, duration of valve implantation, cardiac rhythm,
prevalence of neurologic complications, and presence of dia-
betes mellitus and arterial hypertension on the presence or
absence of MES. All predictors were included as categorical
factors, except for duration of valve implantation (continuous
variable). For this model, MES counts were expressed as 0
(for MES-negative patients) or 1 (for MES-positive patients).
Interobserver variability was evaluated by means of the
Cohen κ statistic.8 Values derived from this evaluation range
between –1 (complete disagreement) and 1 (complete agree-
ment). A value of 0 reflects lack of a relation between the
evaluations of the 2 observers. Acceptable to good agreement
is indicated by values between 0.4 and 0.75, and values
greater than 0.75 indicate an excellent agreement.8
Results
No significant differences in age or sex were evident
between patients having SJM and those having ATS
valves. The duration of valve implantation was longer
in patients with SJM as compared with ATS valves.
This difference was not statistically significant when
patients were split into subgroups according to the dif-
ferent valve positions, but it reached statistical signifi-
cance when all patients were compared. The size of the
implanted valves did not significantly differ between
the 2 groups (Table I). Additionally, prevalence of arte-
rial hypertension and diabetes mellitus was similar for
both groups (21% and 19% for patients with ATS and
22% and 15% for patients with SJM valves, respective-
ly; P = .91 and P = .48, χ2 test). Heart rhythm was sinus
in 60.4% and 55.7% and atrial fibrillation in 34.1% and
36.4% of patients with ATS and SJM valves, respec-
tively; the remaining patients (5.5% and 7.9%, respec-
tively) had a pacemaker. These differences were also
insignificant (P = .72).
MES counts were higher in patients with SJM valves
than in patients with ATS valves. This difference was
statistically significant when all patients were included
in the analysis and also in the subgroups of patients
with AVR and DVR (Table I). Statistically significant
differences in MES prevalence in association with the
valve type were observed in the total patient population
(χ2 test, P = .009; AVR vs MVR, P = .1; AVR vs DVR,
P = .004; MVR vs DVR, P = .2). In the group of
patients with ATS valves, no significant differences in
MES prevalence were evident depending on the valve
position (χ2 test among all patients, P = .1; χ2 test, AVR
vs MVR, P = .1; AVR vs DVR, P = .09; MVR vs DVR,
P = .8). The contrary was true in patients with SJM
valves (χ2 test among all patients, P = .03; χ2 test, AVR
vs MVR, P = .4; Fisher exact test, AVR vs DVR,
1102 Georgiadis et al The Journal of Thoracic and
Cardiovascular Surgery
June 2001
P = .007; Fisher exact test, MVR vs DVR, P = .1). The
Kruskal-Wallis test revealed no significant differences
in MES counts depending on valve position in patients
with ATS or patients with SJM valves (P = .6 and 
P = .3, respectively). The exact MES counts for each
position are listed in Table I.
The Spearman rank correlation revealed a significant
relationship between duration of valve implantation
and MES counts when data from all patients were ana-
lyzed (ρ = 0.25, P = .001). This was also true for
patients with SJM valves (ρ = 0.3, P = .005), but not for
patients with ATS valves (ρ = 0.09, P = .41).
MES counts did not correlate with valve size, except
in patients with an SJM valve in the aortic position
(AVR overall, ρ = 0.19, P = .05; ATS valves,
ρ = –0.001, P = .994; SJM valves, ρ = 0.29, P = .03;
MVR overall, ρ = 0.07, P = .66; ATS valves, ρ = 0.086,
P = .71; SJM valves, ρ = 0.09, P = .73; Spearman rank
correlation).
Results of logistic regression analysis are displayed
in Table II. Valve type was a significant predictor of
MES counts, with SJM valves being a predictor of
higher MES counts than ATS valves; presence of dia-
betes mellitus was a further significant predictor for
lower MES counts.
Linear regression analysis demonstrated a strong cor-
relation between MES counts in the right as compared
with the left middle cerebral artery (r2 = 0.8, P <
.0001). The highest observed discrepancy was 800% (1
MES in the right and 8 in the left middle cerebral
artery). The Cohen κ statistic revealed an excellent
agreement between the 2 observers (κ = 0.82).
A total of 15 patients had had neurologic symptoms
since valve insertion. These consisted of amaurosis
fugax (n = 3), transient ischemic attack (n = 4), and
ischemic stroke (n = 8). All transient ischemic attacks
involved the anterior circulation. Ischemic strokes
involved the anterior circulation in 6 patients (partial
anterior circulation syndrome in all cases) and the pos-
terior circulation in 2 patients (isolated brainstem
infarction, n = 1; brainstem and cerebellar infarction,
n = 1). Six of the 15 patients had SJM valves and 9 had
ATS valves (χ2 test, P = .5). The aortic valve was
replaced in 6 patients (6/110, 5.4%), the mitral in a fur-
ther 6 patients (6/39, 15.3%), and both valves in 4
patients (4/26, 15.3%); these differences did not reach
statistical significance (all patients, χ2 test, P = .1, AVR
vs DVR, P = .22; AVR vs MVR, P = .08; MVR vs
DVR, P = 1; all Fisher exact test).
History of cerebral embolic complications after valve
insertion was not a predictor of MES counts (Table II).
Additionally, no statistically significant differences in
MES counts were evident on direct comparison
between patients with a history of cerebral embolic
complications and the remaining patients (17 [8-31] vs
10 [5-18], P = .1; Mann-Whitney U test).
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Table I. Clinical details and MES counts and prevalence in 179 patients with prosthetic heart valves
Position N Age* (y) Sex (F/M) Duration† (mo) Size* MES per hour† MES (%) Neuro (%)
AVR
ATS 55 62 ± 11 22/33 12 (11-15) 23 ± 3 0.8 (0.3-1.5) 42 7.3
SJM 55 61 ± 10 16/39 15 (12-18) 24 ± 2 8.5 (3.8-13.8) 67 3.6
P value .7‡ .2§ .1 .46‡ .0009 .007§ .7¶
MVR
ATS 21 61 ± 11 15/6 18 (12-19) 28 ± 2 3.5 (1-19.7) 62 19
SJM 18 58 ± 12 8/10 22 (14-29) 28 ± 3 10 (3.5-23.5) 78 11.1
P value .4‡ .09§ .7 .64‡ .3 .3§ .7¶
DVR
ATS 15 64 ± 10 11/4 12 (8-25) 22 ± 2/28 ± 2 2.9 (1-9.8) 67 6.7
SJM 15 58 ± 12 9/6 21 (15-29) 22 ± 2/27 ± 2 30 (10-57.5) 100 13.4
P value .2‡ .4§ .09 .76/.57‡ .004 .04 1¶
All
ATS 91 62 ± 10 48/43 13 (12-16) 1.5 (1-2.5) 51 9.9
SJM 88 60 ± 11 33/55 18 (15-20) 11 (8-16.3) 75 6.8
P value .21‡ .2§ .03 .00001 .0007§ .5§
AVR, Aortic valve replacement; MVR, mitral valve replacement; DVR, dual (aortic and mitral) valve replacement.
*Data expressed as mean ± standard deviation.
†Data expressed as median (95% confidence intervals).
‡Two-sample t test. 
§χ2 Test.
Mann-Whitney U test.
¶Fisher exact test.
Discussion
The main findings of this study were the significant
differences in MES counts between patients with SJM
and those with ATS valves. This finding is further sup-
ported by the results of logistic regression analysis,
demonstrating valve type as an independent predictor
of MES counts. Only 1 previous study compared MES
counts in patients with SJM (n = 200) and ATS valves
(n = 61). No significant differences in MES counts
were noted between the 2 groups, although a tendency
toward higher MES counts in patients with SJM valves
was evident.5 The MES counts reported for SJM valves
were lower than the ones observed in the present study
(4 [3-6] and 11 [8-16], respectively). This was probably
due to the fact that all patients with SJM valves were
examined within 6 months after valve insertion in the
previous study, as compared with a median duration of
18 months in our study. It thus appears probable that
the discrepancies in our results and the ones previously
reported are due to methodologic issues.
The differences in MES counts between patients with
ATS and patients with SJM valves are difficult to
explain assuming formed underlying embolic material,
particularly because the 2 patient groups were compa-
rable in their clinical characteristics, and the same anti-
coagulant regimen was used for all patients. Recent
reports from several research groups add weight to the
hypothesis that the underlying material of MES in
patients with prosthetic valves consists of nitrogen bub-
bles. The observed significant differences in MES
counts between 2 valve types that are quite similar in
design and material composition suggest that even
slight differences in the local fluid mechanical devel-
opment in the vicinity of the bileaflet valve can have a
profound influence on the flow field distant to the
valve. The hydrodynamic characteristics of SJM and
ATS valves were compared in 2 previous studies: sim-
ilar pressure drops across both valves were observed in
the first study, under both steady and pulsatile flow.
Nevertheless, pressure drop was lower in the ATS valve
as compared with the SJM valve under incorporation of
an enlargement instead of a straight downstream con-
duit.9 Significant differences in mean increasing pres-
sure drops and effective orifice areas were noted in the
second study (both ATS > SJM).10 Still, both reports
examined only hydrodynamic performance with the
valve in the mitral position. The causative role of the
aforementioned hydrodynamic findings in the discrep-
ancies in MES counts observed in this study remains to
be evaluated.
The incidence of embolic complications in patients
with SJM valves was examined in several studies11-13
and reported between 1.09%11 and 2.45%13 per patient-
year. Two clinical reports concerning the ATS valve
have been published to date. One thromboembolic
complication was noted in the first, describing 200
patients followed up for 1 to 3 years.14 A single cere-
bral embolic complication is also described in the sec-
ond report, in which results from 100 patients, fol-
lowed up for 5 to 27 months, are presented.15
Obviously, the small size of the aforementioned reports
prohibits clinical comparisons between the 2 groups.
The prevalence of cerebral embolic complications
noted in our study is markedly higher than previously
reported. It must be taken into account, though, that
most symptoms were transient. In fact, most patients
with transient ischemic attacks and amaurosis fugax
reported these incidents only after detailed questioning,
having denied neurologic complications beforehand.
Considering the small sample size of the present study,
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Table II. Evaluation of independent predictors of MES counts using binary logistic regression analysis in 179
patients with prosthetic heart valves
Variables Coefficient SE 95% CI P value
Constant 0.08 0.59 —
Valve type (ATS/SJM) 1.31 0.37 1.78-7.66 .001
Valve position (AVR/MVR) –0.62 0.47 0.21-1.34 .18
Valve position (MVR/DVR) 1.03 0.69 0.73-10.78 .14
Valve duration (mo) 0.01 0.02 0.98-1.05 .47
Cerebral embolic events (yes/no) 1.17 0.78 0.7-14.9 .13
Diabetes mellitus (yes/no) –1.32 0.43 0.11-0.67 .005
Arterial hypertension (yes/no) –0.3 0.43 0.32-1.72 .49
Heart rate (SR vs AF) 0.55 0.42 0.77-3.93 .18
Heart rate (AF vs paced) –0.87 0.69 0.11-1.62 .21
AVR, Aortic valve replacement; MVR, mitral valve replacement; DVR, dual (aortic and mitral) valve replacement; SR, sinus rhythm; AF, atrial fibrillation; SE, stan-
dard error; CI, confidence intervals.
definitive statements on the prevalence of cerebral
embolic events are not warranted. Additionally, our
patients were asked to attend the ultrasound examina-
tion on an outpatient basis; this fact may have biased
our results, because only healthy or at least not heavily
disabled patients were bound to attend. We presume
that the high prevalence of amaurosis fugax in our
study is due to the fact that the ophthalmic artery, with
its small diameter, missing collaterals, and dramatic
neurologic signs, represents a predilection site for
symptomatic embolism.
MES counts were not associated with a history of
cerebrovascular events in our study, which corresponds
to the results of most previous studies. Obviously,
patients were not examined immediately after the cere-
brovascular events occurred, but in some cases as long
as 2 years later, so that a potential relationship in the
acute phase cannot be excluded. On the other hand,
MES counts in patients with prosthetic heart valves
remain relatively constant over time.16
Duration of valve implantation was not identified as
an independent predictor of MES counts in logistic
regression analysis. Still, results from nonparametric
correlation demonstrated a significant influence of
valve duration on MES counts in patients with SJM
valves but not in those with ATS valves. This finding is
difficult to explain, because it suggests a significant
difference in the behavior of the 2 valves. It must be
emphasized that only 1 previous study examining a
homogeneous group, namely patients with Carbo-
medics valves (Sulzer Carbomedics, Inc, Austin, Tex),
described such an influence.2 It has been observed that
the incidence of MES increases with time of implanta-
tion for porcine valves implanted in an animal model,
due to increasing pannus overgrowth on the valve.17 It
is possible that a small difference in tissue encroach-
ment between the ATS and SJM valves may produce a
similar effect with time. Although it appears possible
that the influence of valve duration on MES counts dif-
fers depending on the valve type, we are unable to pro-
vide definitive information on this matter.
No previous study has examined the influence of dia-
betes mellitus on MES counts. The underlying mecha-
nism of this potential effect is unclear. It may be that
blood osmolality influences formation, as well as half-
life, of cavitation bubbles, thus affecting MES counts.
Obviously, several additional parameters would have to
be included in future analyses, particularly adequacy of
diabetes control and actual blood glucose level at the
time of transcranial Doppler study. 
Influence of MES on neuropsychologic deficit in
patients with prosthetic valves was suggested in a
recent study.6 However, the sample size of this study
was quite small, thus prohibiting definitive state-
ments on this matter. Provided that large-scale stud-
ies confirm the influence of MES on cognitive func-
tion, this method is bound to become a standard test
for these patients, at least in the evaluation of new
valve types.
In conclusion, our study provided evidence of signif-
icant differences in MES counts between patients with
ATS and SJM valves. A relation with the prevalence of
neurologic complications could not be established.
Influence of MES on cognitive function remains to be
evaluated.
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